Melphalan uptake in relation to vascular and extracellular space of human lung-tumour xenografts. by Wist, E. et al.
Br. J. Cancer (1981) 43, 458
MELPHALAN UPTAKE IN RELATION TO VASCULAR AND
EXTRACELLULAR SPACE OF HUMAN LUNG-TUMOUR
XENOGRAFTS
E. WISTtt, J. L. MILLARt AND A. J. SHORTHOUSE*
From the tInstitute of Cancer Research, Sutton, Surrey, and *St Mark's Hospital,
City Road, London
Received 30 October 1980 Acceptedl 19 December 1980
Summary.-The effect of melphalan on the growth of4 different lines of human lung-
tumour xenografts has been established. The oat-cell carcinoma was the most sensi-
tive, whereas the adenocarcinoma was the most resistant. Two lines of large-cell
anaplastic carcinomas were intermediate in sensitivity. The differences in sensitivity
were not reflected in the gross uptake of drug into the tumours. There was, with the
exception ofthe adenocarcinoma line, a marked decrease in uptake per g tumour with
increasing tumour size. This was partly caused by a decrease in the vascular supply
in the same tumours with increasing tumour size. Extravasation of plasma proteins
increased with increasing tumour size in all tumours, but was much less pronounced
in the adenocarcinoma than in the other tumour lines. The extracellular volume of
the various tumour lines did not vary with tumour size.
ONE OF THE MOST IMPORTANT RESULTS of
recent research into the xenografting of
human tumours is that it has enabled
examples of chemoresistant and chemo-
sensitive tumours to be established in the
laboratory, and their sensitivity to treat-
ment to be accurately quantified (Steel,
1978; Shorthouse et al., 1980). This then
enables investigations to be made into the
mechanisms underlying sensitivity and
resistance. The aim of this study was to
examine the relationship between re-
sponse and drug access in the treatment of
4 different lines oflung-tumour xenografts
with the alkylating agent melphalan. The
lines were chosen because of their widely
different sensitivity to chemotherapeutic
agents (Shorthouse et al., 1980).
MATERIALS AND METHODS
Drugs.-Melphalan was obtained from
Burroughs Wellcome and [14C]-melphalan by
courtesy of Dr R. Engle of the National
Cancer Institute, Bethesda. The 14C-label
-was positioned in the alkylating inoiety of
the drug, and its distribution therefore re-
flects the distribution of active drug. The
LD1o of melphalan in tumour-bearing ani-
mals was 12 mg/kg. 5mCr-chromium-EDTA,
59Fe-ferric chloride and 1251-human serum
albumin were obtained from the Radio-
chemical Centre, Amersham.
Mice. Male CBA/ca/lac mice bred at the
Institute ofCancer Research breeding centre,
Pollards Wood, were thymectomized at 4
weeks of age and treated with 9 Gy whole-
body irradiation from a 60Co source (0.5 Gy/
min) 3-6 weeks later. The lethal effects ofthis
irradiation were prevented by an i.p. injection
ofAra-C (200 mg/kg) 2 days before irradiation
(Steel et al., 1978).
Tumours.-Four types of bronchial carcin-
omas established as xenograft lines at the
Institute of Cancer Research by one of us
(A.J.S.) were examined: one oat-cell carci-
noma (HX 69), two large-cell anaplastic carci-
nomas (HX 82 and HX 93) and one adeno-
carcinoma (HX 70). Tumours were implanted
bilaterally as solid 2mm pieces into the flanks
ofimmune-deprived mice.
Growth delay.-Groups of tumours were
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selected for chemotherapy when their volume
was 0-2-0-5 cm3, calculated as 1TDd2/6, where
D is the longest diameter of the tumour and
d is the diameter perpendicular to D. They
were randomly allocated to treatment and
control groups, and the therapeutic response
was measured by the in situ endpoint of
growth delay. A minimum of 5 mice per
group was used, giving at least 10 tumours
per treatment group. The difference between
median time to double in volume of treated
and control groups oftumour was determined.
Dividing the result by the median doubling
time ofthe control tumours gave an estimate
of the number of doubling times saved by
each treatment. This parameter allows for
comparisons to be made between tumours of
different growth rates (Kopper & Steel, 1975).
The loss of body weight during the course of
the experiments was minimal.
Druguptake.-14C-melphalan wasdissolved
in acid-alcohol (5M HCI: absolute ethanol,
1: 5) and diluted in saline. The dose of
melphalan given i.v. was 10-11 mg/kg and
the amount of radioactivity per mouse was
0-5-1 0 ,Ci. Four hours later the animals
were killed by anaesthetizing with ether,
making an incision in the axilla and allowing
the animals to bleed freely. This was done to
standardize the amount of blood left in the
tumours. The tumours were dissected out,
put into capsules of combustible polyearbon-
ate and burned in an Intertechnique Oxymat.
In an automatic sequence the 14C-label was
trapped in 20 ml of scintillant (330 ml 2-
methoxyethylamine, 220 ml methanol, 450 ml
toluene and 10 g PPO). The samples were
counted in a liquid scintillation counter
(Intertechnique).
Uptake into muscle was used to correct for
possible differences in injected dose and
degree of bleeding of the animal when killed.
Muscle samples were taken from the quadri-
ceps muscle of both sides and assayed in
in parallel with the tumour specimens.
Assessment of residual red-cell volume,
plasma volume and extracellular volume of
tumours.-The method used is a modification
of the method described by Appelgren et al.
(1973). Briefly, 59Fe-labelled erythrocytes
were produced by injecting mice with a total
of 12 ,uCi of 59Fe-ferric chloride in 0-5%
sodium citrate and 0.75% sodium chloride
over a period of 2 weeks in 4,Ci doses.
Erythrocytes were harvested by bleeding the
animals under anaesthesia from the axilla.
Erythrocytes were washed in heparinized
saline and then mixed with 1251-labelled
human serum albumin and 5ICr chromium-
EDTA in saline. A bolus of0-25 ml containing
labelled erythrocytes (equivalent to 0-2 pXCi
59Fe), 2-5 ,uCi 51Cr-EDTA and 1 ,uCi 125J-
human serum albumin were injected into the
tail veins of tumour-bearing mice. Thirty
minutes after injection the recipient animals
were killed by bleeding freely under ether
anaesthesia. Samples of blood (30 ,A) were
taken from the axilla for radioactivity
measurement and samples were also taken for
the measurement of haematocrit (Hct).
Tumours were dissected out, weighed and
counted in an Intertechnique gamma counter
for 20 min, again using muscle samples for
comparison. The activities in ct/min/ml blood
and ct/min/g tissue were calculated. Using
the haematocrit values the following para-
meters were calculated:
RCV: Residual red cell volume (ml)/g of
tissue = (59Fe activity/g of tissue)/(59Fe acti-
vity/ml blood x Hct/100).
PV: Residual plasma volume (ml)/g of
tissue = (1251 activity/g of tissue)/(1251 acti-
vity/ml blood x (1-Hct/100)).
ECV: Extracellular volume (ml)/g oftissue
= (51Cr activity/g of tissue)/(5lCr activity/ml
blood x (1-Hct/100)).
PV measures both intravascular plasma
and plasma extravasated during the 30 min.
The extravascular plasma volume (EPV) was
calculated as:
EPV =PV-intravascular plasma volume
(IPV);
IPV= (RCV x 100/Hct) x (1-Hct/100).
The EPV/IPV ratio is a measure of the
extravasation of plasma protein where varia-
tions in blood supply and hence the plasma
supply are adjusted for.
RESULTS
Growth delay
The effect of melphalan on the growth
of the 4 different xenograft lines is shown
in Fig. 1. The growth-delay values for each
ofthe tumours are presented in the Table.
On the basis of these values the tumours
in order ofincreasing sensitivity were HX
70, 82, 93, 69. Data on the uptake of 14C.
melphalan into HX 69, 82 and 93 are pre-
sented in Fig. 2. There was a striking
decrease in drug uptake per g tumour
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FiG. 1.-The effect of melphalan on the growth of 4 lung-tumour xenografts. A: Adenocarcinoma,
HX70. B: Large-cell anaplastic carcinoma, HX82. C: Oat-cell carcinoma, HX69. D: Large-cell
anaplastic carcinoma, HX93. The points plotted represents median values. Arrow indicates day
of drug administration. 0 Control. 0 Treated: 10 mg/kg melphalan in A, B and D; 6 mg/kg mel-
phalan in C. A 12 mg/kg melphalan in C.
tissue with increasing tumour size for all
3 lines, and the decrease seemed linearly
related to log tumour weight. The uptake
of drug per g tumour into a tumour of 2 g
is only about 10% of the uptake into a
tumour of 0.1 g. The lines drawn are linear
regression lines and their coefficients of
correlation are HX 69: 0-92 (P < 0-001),
HX 82: 0-94 (P<0.001) and HX 93: 0-54
(P < 0.05). The slope for HX 69 is signifi-
cantly less than that for HX 82 (P< 0.05);
other differences are not significant.
The relative 14C uptake per g (tumour/
muscle) at a tumour weight of 0-35 g is
presented in the Table. This weight is the
mean weight for tumours used in growth-
delay studies. The uptake of 14C-melph-
alan into the adenocarcinoma HX 70 did
not vary with tumour size in the range of
sizes examined (0.1-2-5 g). Relative 14C
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TABLE.-Growth delay and other valuesfor each of the tumours
Xenograft
line Histology
HX70 Adenocarcinoma
HX82 Large-cell anaplastic ca
HX93 Large-cell anaplastic ca
HX69 Oat-cell carcinoma
Growth
delay
(doubling
times
saved) after
10 mg/kg
melphalan
0-38
0-82
1-3
4-5
Relative
14C-
melphalan
uptake
(tumour/
muscle)
by 0 35g
tumours
1-19
0-78
0 94
0-66
Residual
red-cell
volume
( tl/g)
0 35g
tumours
6-3
6-3
8-6
2-7
Extra-
vascular
plasma
volume
(Id/g)
13*1
35-2
37-2
31-2
Extra-
cellular
volume
(yd/g)
132
178
210
152
1.25
E
1.00 . > 0
N° 0.75 A -
0.25
0.05 0.1 0.5 1.0
Tumour wt(g)
FIG. 2. Relative uptake of 14C-melphalan
per g (tumour/muscle) as a function of
tumourweight. HX69: - -- - -, HX82:
- - -, HX93: O
uptake (tumour/muscle) was 1-19 + 0.19
(Table). This is an uptake as high as that
only seen in the small tumours of HX69,
82 and 93 (Fig. 2).
Residual red cell volume, plasma volume,
extracellular volume and vascular perme-
ability
The residual red-cell volumes of HX 69,
82 and 93 are shown in Fig. 3. As with
drug uptake there is a striking decrease in
RCV with increasing tumour size and the
decrease is linearly related to log tumour
weight.
The linear regression lines had the fol-
lowing coefficients of correlation: HX 69:
0-73 (P<0-02), HX 83: 0-91 (P<0.01) and
HX 93: 0-79 (P < 0-02). A statistical com-
parison of the slopes of the lines revealed
no significant differences.
The residual blood volume ofHX 70 did
0.01 0.1 1.0
Tumour wt(g)
FIG. 3.-Residual red-cell volume of lung
tumour xenografts as a function of tumour
weight. HX69: - - - A - - -, HX82:
-- - -,HX93: 0O
not decrease with increasing tumour
weight in the range examined (0-075-
1-33 g). The mean RCV was 6-32+0-36
pi/g.
In all 4 tumours there was poor corre-
lation between residual plasma volume
(PV) and tumour size, and also between
the volume of extracellular plasma (EPV)
and tumour size. The mean values ofEPV
are presented in the Table. The EPV in
the adenocarcinoma (HX 70) is less than
40% of the EPVs in the 3 other tumours.
Because the blood supply as reflected by
RCV decreased with increasing tumour
size, the ratio between extra- and intra-
vascular plasma (EPV/IPV) was deter-
mined. In all 4 tumours the ratio increased
with tumour size, as an indication of
increased leakage (Fig. 4). The increase
was linearly related to the log tumour
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FIG.,. 4. Extravascular plasma \oluIme(EPV)/
intravascular plasma volume (IPV) as
a functioni of tiumouir weiglht. H_X70:
--* HX82: - HX6I9:
--A-
weight for HX 69, 70 and 82. The linear
regression line for HX 93 had a small
coefficient of correlation, and is left out
for the sake of clarity, but even in this
tumour line EPV/IPV tended to be higher
in big tumours than in small. The linear
regression lines for the other tumours had
the following coefficients of correlation:
HX 69: 0.56 (P<010), HX 70: 0*74
(P<0*001) and HX 82: 0*78 (P<0*02).
The increase in leakage with increasing
tumour size was much less pronounced in
HX 70 than in the other tumour lines. The
oat-cell carcinoma HX 69 showed the
greatest vascular leakage.
The extracellular volumes of HX 69, 70
and 93 showed no variation with tumour
weight. Mean values are presented in the
Table. In HX 82 there was a significant
decrease in ECV with increasinog size. At a
tumour weight of 0.02 g the ECY' was
about 280 ,ll/g, wvhereas at a tumour
weight of 1 g the ECVT was about 140 ltl/g.
AIn interpolated value at a tumour weight
of 0*35 g is presented in the Table.
IDISCUSSION
In this study we have examined 4
human tumour xenografts which differ
widely in their sensitivity to melphalan.
The oat-cell carcinoma HX 69 was about
12 x as sensitive to melphalan as the
adenocarcinoma HX 70, in terms of
growth delay (Table). The 2 other tumour
lines were intermediate in sensitivity. In
spite of this big difference in chemosensi-
tivity, the uptake of 14C-melphalan into
gross tumours did not reveal a similar
difference. In fact the uptake ofmelphalan
into an oat-cell tumour of0 35 g (the mean
weigh-t oftumours usually used forgrowth-
delay studies) was just 55%0 of that into
an adenocarcinoma. The large-cell tumours
had intermediate uptakes, and the differ-
ence between the 2 was not significant. A
similar lack of correlation between drug
uptake and chemosensitivity has been re-
ported by Rutty et al. (1978) comparing
the uptake of hexamethylmelamine into
P246 bronchial carcinoma xenografts and
ADJ/PC6 plasma-cell animal tumours.
With the exception of HX 70 the uptake
of melphalan into tumours decreased with
increasing tumour weight (Fig. 2). This
raised the question of drug access to the
various tumours. We therefore examined
the vascular supply of the tumours, and
looked at parameters such as extracellular
volume and extravasation of plasma pro-
teins. With theexceptionoftheadenocarci-
noma HX 70, the residual red-cell volume
decreased with increasing tumour weight
(Fig. 3). The decrease in uptake of melph-
alan with increasing tumour weight in the
oat-cell tumour xenograft and the large-
cell anaplastic tumour xenografts seems,
therefore, at least partly the result of a
decreased blood supply. The residual red-
cell volume of 0-35g oat-cell tumours were
only about 4300 that of the adenocarci-
noma. This correlates well with the drug
uptake in oat-cell tumours being about
550 of that of the adenocarcinoma.
The residtual red-cell volumes of the 4
tumour xeniograft lines are of the same
magnitude as those of Song & Levitt
(1971) who reported a total blood volume
of 7*9 ,ul/g wet weight of rat Walker
carcinoma 256.
The extracellular volume seemed not to
influence the drug uptake, nor did the
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extravasation of plasma proteins. The
extravasated plasma volume during the
30 min after injection varied between 13-1
and 37-2 pl/g. This is of the same order as
that reported for rat Walker carcinoma
(Song & Levitt, 1971) in which the extra-
vasation is reported to be - 97 jul/g wet
weight/h. The extravasation of plasma
protein in the tumours was about 2-5
times that seen in muscle. The extra-
vasation relative to the plasma supply did
however increase markedly with tumour
weight in HX 69, 82 and 93, whereas the
increase in EPV/IPV ratio in HX 70 was
slight.
These findings may indicate that the
vascular system of HX 70 does not break
down as quickly with increasing tumour
size. The neovascularization of this
tumour could be more adequate than in
the other 3 lines. It is possible that the
production of tumour angiogenesis factors
(reviewed by Folkman, 1975) is more
efficient in HX 70 than in the other lines;
which would have impact on the growth of
tumours in humans, and add to the prob-
lems in treating this chemoresistant
cancer.
In view of the lack of correlation be-
tween drug uptake and chemosensitivity,
the cause of the reported differences in
sensitivity to melphalan in these tumour
lines must be sought on the cellular level.
Work is in progress investigating drug
uptake and chromatin binding in single-
cell preparations of these tumours. The
development and use of spheroids from
tumour cells also open interesting possi-
bilities in studying the mechanisms under-
lying chemosensitivity and resistance.
An autoradiographic study was attemp-
ted, to look at drug distribution within the
tumours, but failed because the specific
activity of the labelled melphalan was not
high enough to yield results with a
realistic exposure time.
One of the encouraging findings in this
study is the marked growth delay caused
by melphalan in oat-cell tumours. The
effect was nearly linearly related to drug
dose (unpublished observation). This sug-
gests a role of high-dose melphalan in the
treatment of oat-cell carcinoma in man.
E. Wist is a research fellow of the Norwegian
Cancer Society. We thank Dr G. G. Steel for helpful
discussion andl support (luring the preparation of the
manuscript.
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